Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Anja Möricke, MD, André Schrauder, MD, Martin Zimmermann, PhD, Georg Mann, MD, Andishe Attarbaschi, MD, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Martin Stanulla, MD, MSc, Gunnar Cario, MD, Alfred Reiter, MD, Felix Niggli, MD, Claus R Bartram, MD, Martin Schrappe, MD

Blood (2011) 118 (21): 1504.

https://doi.org/10.1182/blood.V118.21.1504.1504

Published: 2011

Journal Articles

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Jan Zuna, MD, PhD, Mari Arens, Rolf Koehler, PhD, Renate Panzer-Grümayer, MD, Anja Möricke, MD, Claus R Bartram, MD, Ruth Joas, Eva Fronkova, Gunnar Cario, MD, Martin Stanulla, MD, MSc, Martin Zimmermann, PhD, Jan Trka, MD, PhD, Jan Stary, M.D., Andishe Attarbaschi, MD, Georg Mann, MD, Martin Schrappe, MD, André Schrauder, MD

Blood (2011) 118 (21): 756.

https://doi.org/10.1182/blood.V118.21.756.756

Published: 2011

Journal Articles

Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation

Daniel Steinbach, MD, Bernhard Wilhelm, MD, Hans-Rudolf Kiermaier, MD, Ursula Creutzig, MD, Martin Schrappe, MD, Martin Zimmermann, Klaus-Michael Debatin, MD, Bernd Gruhn, MD, Arend von Stackelberg, MD, Heribert Jürgens, MD, Brigitte Strahm, MD, Dirk Reinhardt, MD, PhD, Anja Möricke, MD

Blood (2010) 116 (21): 3243.

https://doi.org/10.1182/blood.V116.21.3243.3243

Published: 2010

Journal Articles

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 1718.

https://doi.org/10.1182/blood.V116.21.1718.1718

Published: 2010

Journal Articles

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Petra Breithaupt, PhD, Barbara Meissner, MD, Martin Zimmermann, Anja Möricke, MD, André Schrauder, MD, Jochen Harbott, Wolf-Dieter Ludwig, MD, PhD, Rolf Köhler, PhD, Claus R Bartram, MD, Martin Schrappe, MD, Gunnar Cario, MD, Martin Stanulla, MD, MSc

Blood (2010) 116 (21): 409.

https://doi.org/10.1182/blood.V116.21.409.409

Published: 2010

Journal Articles

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.

Martin Stanulla, MD, Elke Schäffeler, PhD, Silke Pohlschmidt, Martin Zimmermann, PhD, Anja Möricke, MD, Gunnar Cario, MD, Andre Schrauder, MD, Karl Welte, MD, Jochen Harbott, PhD, Wolf-Dieter Ludwig, MD, Alfred Reiter, MD, Michel Eichelbaum, MD, Martin Schrappe, MD, Matthias Schwab, MD

Blood (2009) 114 (22): 2625.

https://doi.org/10.1182/blood.V114.22.2625.2625

Published: 2009

Journal Articles

Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000.

Anja Möricke, MD, Martin Zimmermann, PhD, Jeanette Greiner, MD, André Schrauder, MD, Hansjörg Schmid, MD, Martin Stanulla, MD, Andishe Attarbaschi, MD, Alfred Reiter, MD, Georg Mann, MD, Martin Schrappe, MD

Blood (2009) 114 (22): 990.

https://doi.org/10.1182/blood.V114.22.990.990

Published: 2009

Journal Articles

No Influence on the Incidence of Osteonecroses When Dexamethasone Replaces Prednisone during Induction Treatment for Childhood ALL: Results of Trial ALL-BFM 2000.

Anja Möricke, MD, Martin Zimmermann, PhD, Andre Schrauder, MD, Martin Stanulla, MD, Hansjörg Schmid, MD, Rüdiger Fengler, MD, Michael Frühwald, MD, Georg Mann, MD, Martin Schrappe, MD

Blood (2008) 112 (11): 899.

https://doi.org/10.1182/blood.V112.11.899.899

Published: 2008

Journal Articles

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Martin Schrappe, MD, Martin Zimmermann, PhD, Anja Möricke, MD, Georg Mann, MD, Maria Grazia Valsecchi, PhD, Claus R Bartram, MD, Andrea Biondi, MD, Renate Panzer-Grümayer, MD, André Schrauder, MD, Franco Locatelli, MD, Alfred Reiter, MD, Giuseppe Basso, MD, Felix Niggli, MD, Maurizio Aricò, MD, Valentino Conter, MD

Blood (2008) 112 (11): 7.

https://doi.org/10.1182/blood.V112.11.7.7

Published: 2008

Journal Articles

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Andrea Biondi, André Schrauder, Maria Grazia Valsecchi, Claus R Bartram, Georg Mann, Giulio De Rossi, Anja Möricke, Rosanna Parasole, Jochen Harbott, Chiara Messina, C. Rizzari, Giuseppe Masera, Martin Schrappe

Blood (2008) 112 (11): 1511.

https://doi.org/10.1182/blood.V112.11.1511.1511

Published: 2008

Journal Articles

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Blood (2007) 110 (11): 1425.

https://doi.org/10.1182/blood.V110.11.1425.1425

Published: 2007

Journal Articles

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Anja Möricke, MD, Alfred Reiter, MD, Martin Zimmermann, PhD, Helmut Gadner, MD, Martin Stanulla, MD, Wolf-Dieter Ludwig, MD, Jochen Harbott, PhD, Georg Mann, MD, Felix Niggli, MD, Günter Henze, MD, Karl Welte, MD, Thomas Klingebiel, MD, Charlotte Niemeyer, MD, Felix Zintl, MD, Hansjörg Riehm, MD, Martin Schrappe, MD

Blood (2007) 110 (11): 584.

https://doi.org/10.1182/blood.V110.11.584.584

Published: 2007

Journal Articles

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Anja Möricke, MD, Richard Ratei, MD, Wolf-Dieter Ludwig, MD, PhD, Jochen Harbott, PhD, Arndt Borkhardt, MD, PhD, Susanne Viehmann, PhD, Martin Zimmermann, PhD, Helmut Gadner, MD, PhD, Hansjörg Riehm, MD, PhD, Martin Schrappe, MD, PhD

Blood (2004) 104 (11): 1957.

https://doi.org/10.1182/blood.V104.11.1957.1957

Published: 2004

NARROW

Major Improvement of Outcome in Pediatric High-Risk Acute Lymphoblastic Leukemia by Addition of BFM Chemotherapy Element “Phase IB”: A Comparative Data Analysis of Trials ALL-BFM 95 and ALL-BFM 2000

Repeated Bone Marrow Aspiration At the End of Induction Therapy: Implications for Treatment Stratification in Paediatric Acute Lymphoblastic Leukaemia

Thirty Percent Long Term Survival In Children with Acute Leukemia and Complications Requiring Mechanical Ventilation

C20orf94 deletion Is Strongly Associated with TEL/AML1 Rearrangement and Links Illegitimate V(D)J Recombination with Gender Bias In Childhood Acute Lymphoblastic Leukemia

IKZF1 Deletion Is An Independent Predictor of Outcome In Pediatric Acute Lymphoblastic Leukemia Treated According to the ALL-BFM 2000 Protocol

Thiopurine Methyltransferase Genetics Is Associated with Treatment Outcome and Hepatic Toxicity in Pediatric Patients with Acute Lymphoblastic Leukemia: a Report From the ALL-BFM Study Group.

Prospective Evaluation of Thromboembolic Events During Chemotherapy of Childhood Acute Lymphoblastic Leukemia: Results of Randomized Trial ALL-BFM 2000.

No Influence on the Incidence of Osteonecroses When Dexamethasone Replaces Prednisone during Induction Treatment for Childhood ALL: Results of Trial ALL-BFM 2000.

Dexamethasone in Induction Can Eliminate One Third of All Relapses in Childhood Acute Lymphoblastic Leukemia (ALL): Results of An International Randomized Trial in 3655 Patients (Trial AIEOP-BFM ALL 2000)

Impact of Minimal Residual Disease (MRD) on Prognosis in Children with Philadelphia Positive Acute Lymphoblastic Leukemia (ALL) Treated in the AIEOP-BFM ALL 2000 Study.

Prognostic Impact of Minimal Residual Disease (MRD) in Children Is Different in B or T Lineage Acute Lymphoblastic Leukemia: Results of Trial AIEOP-BFM ALL 2000.

Risk-Adjusted Therapy of Acute Lymphoblastic Leukemia Can Decrease Treatment Burden and Improve Survival: Treatment Results of 2169 Unselected Pediatric and Adolescent Patients Enrolled in the Trial ALL-BFM 95.

Prognostic Factors in CD10 Negative Precursor B-Cell Acute Lymphoblastic Leukemia in Children: Data from Three Consecutive Trials ALL-BFM 86, 90, and 95.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only